title: Prevention of ovarian hyperstimulation syndrome in a rat model: comparison of the efficacy of tocilizumab with that of ranibizumab, cabergoline, and a gonadotropin-releasing hormone antagonist.
abstract: The aim of the study is to investigate the effects of the interleukin-6 (IL-6) blocker tocilizumab in a hyperstimulated rat model and compare it with ranibizumab, a gonadotropin-releasing hormone antagonist (GnRHA), and cabergoline. Forty-seven rats were randomly divided into the following seven groups: Group 1: OHS; Group 2: OHS+ GnRHA; Group 3: OHS + ranibizumab; Group 4: OHS + cabergoline; Group 5: OHS + low-dose tocilizumab (TL); Group 6: OHS + high-dose tocilizumab (TH); Group 7: sham. Ovarian weight was significantly lower only in the ranibizumab group than in the OHS group. Estrogen levels were significantly lower in the GnRHA group than in the OHS and the treatment groups. Progesterone levels were significantly lower in the ranibizumab, cabergoline, and TL groups than in the OHS group. Among the treatment groups, corpus luteum counts were lower than in the OHS group. Corpus luteum counts were lowest in the tocilizumab groups. IL-6 intensity was lower in all treatment groups than in the OHS group. In the ranibizumab group IL-6 intensity was the lowest. The TL group did not significantly differ from the GnRHA and cabergoline groups regarding IL-6 expression. Ovarian VEGF expression was significantly lower in all treatment groups. For the TL, ranibizumab, and cabergoline groups VEGF intensity was similar. Tocilizumab may be a new strategy for preventing ovarian hyperstimulation syndrome by inhibition of IL-6.
authors.affiliation: a Department of Obstetrics and Gynecology , Balikesir University Faculty of Medicine , Balikesir , Turkey .
authors.forename: Mine Islimye
authors.initials: MI
authors.lastname: Taskin
authors.affiliation: b Dr. Zekai Tahir Burak Women's Health Investigation and Education Hospital , Ankara , Turkey .
authors.forename: Onur
authors.initials: O
authors.lastname: Topcu
authors.affiliation: c Department of Histology and Embryology , Erciyes University Faculty of Medicine , Kayseri , Turkey .
authors.forename: Arzu
authors.initials: A
authors.lastname: Yay
authors.affiliation: d Department of Physiology , and.
authors.forename: Gulten
authors.initials: G
authors.lastname: Erken
authors.affiliation: c Department of Histology and Embryology , Erciyes University Faculty of Medicine , Kayseri , Turkey .
authors.forename: Esra
authors.initials: E
authors.lastname: Balcioğlu
authors.affiliation: a Department of Obstetrics and Gynecology , Balikesir University Faculty of Medicine , Balikesir , Turkey .
authors.forename: Ertan
authors.initials: E
authors.lastname: Adali
authors.affiliation: e Department of Biochemistry , Balikesir University Faculty of Medicine , Balikesir , Turkey.
authors.forename: Adnan Adil
authors.initials: AA
authors.lastname: Hismiogulları
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000077465:Cabergoline; D004873:Ergolines / Q000627:therapeutic use*; D004967:Estrogens / Q000097:blood; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D015850:Interleukin-6 / Q000032:analysis; D016471:Ovarian Hyperstimulation Syndrome / Q000473:pathology / Q000517:prevention & control*; D010053:Ovary / Q000737:chemistry / Q000473:pathology; D011374:Progesterone / Q000097:blood; D000069579:Ranibizumab / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis / Q000037:antagonists & inhibitors; D000093242:Interleukin-6 Inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000077465:Cabergoline; D004873:Ergolines; D004967:Estrogens; D007987:Gonadotropin-Releasing Hormone; D015850:Interleukin-6; D011374:Progesterone; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A; D000093242:Interleukin-6 Inhibitors; C502936:tocilizumab
keywords: Endometriosis; IL-6; rat; tocilizumab